Intervention Study on Digital Health Management

Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-65
SponsorShanghai 10th People's Hospital

About this trial

The aim of this study is to construct a digital precision intervention system for cardiometabolism disorders based on the characteristics of the Chinese population, focusing on the core components of metabolic syndrome such as hypertension, hyperglycemia, and obesity. Through dynamic monitoring of wearable devices, the individualized risk factors (including genetic predisposition, lifestyle, and psychological factors) of metabolic disorders were systematically analyzed, and dynamic intervention strategies were formulated accordingly. The closed-loop management of "monitor-feedback-optimization" based on the digital platform will provide patients with one-stop metabolic risk assessment and panoramic health management plan, realizing a paradigm shift from "generalized intervention" to "precise regulation". By reducing the abnormal fluctuations of key metabolic indicators such as blood pressure, blood glucose, and blood lipids, the risk of cardiovascular events will eventually be reduced, the long-term quality of life of patients will be improved, and a practical path of "digital therapy" can be promoted for the prevention and control of chronic diseases in China

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Diastolic hypertension (systolic blood pressure < 140 MMHG and diastolic blood pressure ≥90mmHg)

Glycosylated hemoglobin (6.0-6.5)

Obesity (BMI≥28kg/m²)

Mild hyperlipemia: total cholesterol (TC) ≥5.2 mmol/L and < 6.2 mmol/L, or low-density lipoprotein cholesterol (LDL-C) ≥3.4 mmol/L and < 4.1 mmol/L 3. Antihypertensive or lipid-lowering medications have not been started 4. Use a smartphone and volunteer

Disqualifiers

Complicated with chronic liver and kidney disease, coronary heart disease, heart failure and severe valvular disease

Previous cardiovascular and cerebrovascular events

Diastolic blood pressure ≥99mmHg

Glycated hemoglobin ≥6.5

Trial design

Design model

Single group

Treatments tested in this trial

  • Bracelet, assistant, APP: the "golden triangle" of smart life

    Other intervention

    The lifestyle intervention was carried out through the bracelet, Little Assistant and Keyhealth APP for 24 weeks, and the daily data synchronization of the APP and weekly AI feedback were performed. After 24 weeks, blood glucose, blood lipid, blood pressure, CAI and other indicators were monitored.

Treatment groups

300 Participants
are divided into 1 treatment group
Group A: Cardiovascular digital management groupExperimental treatment 1 intervention

Trial outcomes

Primary outcomes

1

Changes in diastolic blood pressure after 24 weeks

Time frame
24 weeks following intervention

Secondary outcomes

1

Values for changes in Hba1c or BMI or CAI after 24 weeks

Time frame
24 weeks following intervention

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

This trial is not recruiting at the moment. You can still explore other options: